ARRHYTHMIA DETECTION/ALARM DEVICE CLASS II CONSIDERATION RECOMMENDED
This article was originally published in The Gray Sheet
Executive Summary
ARRHYTHMIA DETECTION/ALARM DEVICE CLASS II CONSIDERATION RECOMMENDED by the Health Industry Manufacturers Association in comments on FDA's proposed strategy to call for premarket approval applications for remaining preamendment Class III devices. In an Aug. 31 letter written for HIMA by the Washington, D.C. law offices of King & Spaulding, the association says FDA should include the devices with those the agency thinks have "a high potential for reclassification."
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.